This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Swoboda, R. K. Articles by Herlyn, D. Search for Related Content PubMed PubMed Citation Articles by Swoboda, R. K. Articles by Herlyn, D.

Shared MHC Class II–Dependent Melanoma Ribosomal Protein L8 Identified by Phage Display

¹ The Wistar Institute; ² Center for Epidemiology and Biostatistics and ³ Abramson Cancer Center, University of Pennsylvania; Departments of ⁴ Pathology, ⁵ Medicine, and ⁶ Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and ⁷ Department of Transfusion Medicine Clinical Center, NIH, Bethesda, Maryland

Requests for reprints: Dorothee Herlyn, Immunology Program, The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104. Phone: 215-898-3962; Fax: 215-898-0980; E-mail: dherlyn{at}wistar.org.

Antigens recognized by T helper (Th) cells in the context of MHC class II molecules have vaccine potential against cancer and infectious agents. We have described previously a melanoma patient's HLA-DR7–restricted Th cell clone recognizing an antigen, which is shared among melanoma and glioma cells derived from various patients. Here, this antigen was cloned using a novel antigen phage display approach. The antigen was identified as the ribosomal protein L8 (RPL8). A peptide of RPL8 significantly stimulated proliferation and/or cytokine expression of the Th cell clone and lymphocytes in four of nine HLA-DR7⁺ melanoma patients but not in healthy volunteers. The RPL8 antigen may represent a relevant vaccine target for patients with melanoma, glioma, and breast carcinoma whose tumors express this protein. [Cancer Res 2007;67(8):3555–9]